← board
HCWB
HCW Biologicsdistress 9/10 · high distress / dilution risk$3.25-3%today-91% from 52w high
Dermatology 1
Lead: alopecia areata
Revenue
pre-revenue
Liquidity
$6M
Runway
0.5 yrs
Shares 1y
+213%
Price & events
-61.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.9%
1D
-20.0%
1W
-49.9%
1M
+32.4%
3M
-59.9%
6M
-87.8%
1Y
-97.7%
2Y
-99.7%
5Y
-99.8%
All
Overview
- Market Cap
- $21.87M
- Enterprise Value
- $20.64M
- Volume
- 24.64K
- 52 Week Range
- $1.61 – $36.12
- Total Shares
- 6.73M
- Float Shares
- 975.08K
- Short %
- 2.78%
- % Held by Insiders
- 9.24%
- % Held by Institutions
- 8.59%
- RVOL
- 0.21x
- Beta
- 2.30
Pipeline stages · 1 programs
HCW9302, an IL-2 fusion protein
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-16 Estimated 50% readout ~2026-08-15 | Phase 1 | HCW9302, an IL-2 fusion protein | Alopecia Areata(AA) | 30 | recruiting |
Catalyst news & presentations · 3
- year-end 2026Guided 40%readoutPhase 1HCW9302 · Establish Recommended Phase 2 DoseSEC 8-K
- November 18, 2025trial initiationsecondaryPhase 1HCW9302 · First patient dosed in Phase 1 multi-center trialSEC 8-K
- 2025-05-29partnershipHCW11-006 · WY Biotech completed due diligence and elected to continue the license agreement, earning HCW Biologics a $7.0M upfront fee.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $30 (+824% upside) · 1 analysts
- 2026-05-28Maxim GroupBuy
- 2025-05-29Maxim GroupBuy
Competitors — alopecia areata
Recent news
- 2026-07-23HCW Biologics Reaches Milestones for Its Proprietary - GlobeNewswire
- 2026-07-23HCW Biologics’ Cancer Candidate Targets Tissue Factor in Solid Tumors - Stock Titan
- 2026-07-16HCW Biologics (HCWB) seeks $5.6M in stock sale to fund trials, repay debt - Stock Titan
- 2026-07-01HCW Biologics (HCWB) clears $2.8M disputes and $1.1M lien - Stock Titan
- 2026-06-30HCW Biologics clears Nasdaq bid-price rule, then splits stock 1-for-6 - Stock Titan
- 2026-06-30HCW Biologics (NASDAQ: HCWB) regains bid-price compliance and sets 1-for-6 reverse split - Stock Titan
- 2026-06-30HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - GlobeNewswire
- 2026-06-26HCW Biologics (NASDAQ: HCWB) enacts 1-for-6 reverse split to support Nasdaq bid-price compliance - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.